Table 3.
Biomarker Result | p16 IHC-Negative CIN2 | p16 IHC-Positive CIN2 | CIN3 | |||||
---|---|---|---|---|---|---|---|---|
N | % | N | % | N | % | P a | P trend b | |
HPV16+ | 91 | 21.41 | 415 | 38.18 | 658 | 54.47 | <.001 | <.001 |
HSIL+ cytologyc | 80 | 21.11 | 206 | 21.02 | 447 | 42.53 | <.001 | <.001 |
EP diagnosis of CIN3+ | 22 | 5.18 | 249 | 22.91 | 789 | 65.31 | <.001 | <.001 |
EP diagnosis of CIN2+ | 118 | 27.76 | 700 | 64.40 | 1064 | 88.08 | <.001 | <.001 |
HPV16+, HSIL+, and/or EP diagnosis of CIN3+ | 163 | 38.35 | 633 | 58.23 | 1038 | 85.93 | <.001 | <.001 |
HPV16+, HSIL+, and EP diagnosis of CIN3+ | 3 | 0.71 | 27 | 2.48 | 192 | 15.89 | <.001 | <.001 |
Below the individual biomarker results, the relationships of the diagnoses with combinations of any (or) or all (and) biomarkers are shown.
p16 IHC–positive CIN2 versus CIN3.
Trend for p16 IHC–negative CIN2 versus p16 IHC–positive CIN2 versus CIN3.
Forty-six p16 IHC–negative CIN2, 107 p16 IHC–positive CIN2, and 157 CIN3 missing antecedent cytology.